Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 3;16(10):e70800.
doi: 10.7759/cureus.70800. eCollection 2024 Oct.

Effects of Ursodeoxycholic Acid Treatment for Intrahepatic Cholestasis of Pregnancy on Maternal and Fetal Outcomes

Madiha Iqbal  1 , Zia Muhammad  2 , Naheed Akhter  3 , Samina Shams Alam  4
Affiliations

Effects of Ursodeoxycholic Acid Treatment for Intrahepatic Cholestasis of Pregnancy on Maternal and Fetal Outcomes

Madiha Iqbal et al. Cureus. .

Abstract

Background: Intrahepatic cholestasis of pregnancy (ICP) appears in the second or third trimester of pregnancy and is characterized by pruritus and elevated blood bile acid (BA) levels. Complications from these symptoms may include preterm birth, fetal distress, or stillbirth. Although the precise causes of ICP are unknown, genetic, hormonal, and environmental variables may be involved. First-line treatment for ICP is ursodeoxycholic acid (UDCA), which improves bile flow and consequently lowers BA levels and pruritus.

Objective: The objective of this study is to investigate the impact of UDCA therapy on maternal and fetal outcomes in women with ICP.

Materials and methods: This was a prospective observational study of 123 pregnant women with ICP, aged between 20 and 45 years who were diagnosed clinically (pruritus) supported by abnormal laboratory results including elevated serum BA levels, and abnormalities in liver function tests, over the course of three years, from July 2021 to June 2024. Every patient received UDCA, commencing at 10-15 mg/kg/day and being titrated according to clinical guidelines. Maternal and fetal outcomes were tracked for the duration of the pregnancy, with data being collected at baseline (15 ± 1 weeks) and every two weeks until delivery.

Results: The mean age of the study participants was 29.6 ± 5.4 years, with the youngest patient being 20 years and the oldest being 45 years. Most women were multipara 65.9%, and the mean BMI was 27.8 ± 3.5 kg/m ². The mean time of gestational age at ICP diagnosis was 31.2 ± 2.7 weeks, and the time of gestational age at delivery was 37.1 ± 2.4 weeks. On average, the serum BA level at diagnosis was 23.5 ± 8.1 µmol/L.

Conclusion: In the majority of ICP patients with good fetal outcomes, UDCA not only normalizes serum BA levels but also reduces maternal symptoms. In addition to addressing patient response variability to this therapy and optimizing dissemination procedures, the researchers expect that the results of this study will support the continued use of UDCA as first-line treatment for ICP, at least until more evidence becomes available.

Keywords: fetal; icp; maternal; serum bile acid; udca.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent was obtained or waived by all participants in this study. Hospital Research and Ethical Committee, Hayatabad Medical Complex issued approval 2290. The ethical review board of Hayatabad Medical Complex has reviewed the article in accordance with the Declaration of Helsinki (2013) and found it to meet the requirement and be approved . Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Normal and non-normalized bile acid levels
See this image and copyright information in PMC

References

    1. Genetically predicted lipids mediate the association between intrahepatic cholestasis of pregnancy and cardiovascular disease. Cui J, Zhai Q, Chen M, Yang Z. Front Cardiovasc Med. 2024;11:1401010. - PMC - PubMed
    1. Intrahepatic cholestasis of pregnancy. Geenes V, Williamson C. World J Gastroenterol. 2009;7:2049–2066. - PMC - PubMed
    1. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Bacq Y, Sentilhes L, Reyes HB, et al. Gastroenterology. 2012;143:1492–1501. - PubMed
    1. Intrahepatic cholestasis of pregnancy. Williamson C, Geenes V. Obstet Gynecol. 2014;124:120–133. - PubMed
    1. Evaluating the utility of liver transaminases as predictors of feto-maternal outcome in lieu of serum bile acids in intrahepatic cholestasis of pregnancy: a prospective observational study. Misra D, Singh N, Faruqi M, Tiwari V, Kumar V, Zafar F. https://wydawnictwo.umed.pl/wp-content/uploads/2022/11/MONOGRAFIA_08_202.... J Obstet Gynaecol India. 2024;74:113–118. - PMC - PubMed

LinkOut - more resources